Stock Track | Quidel Plunges 17.67% in Post-Market on Q1 Revenue Miss and Macro Pressures

Stock Track

Apr 16

Quidel's stock plummeted 17.67% in post-market trading, following the company's announcement of preliminary first-quarter revenue that fell significantly short of analyst expectations.

The in vitro diagnostics company expects preliminary unaudited Q1 2026 revenue of $615 million to $620 million, well below the $677.8 million analysts had anticipated. The shortfall is attributed to multiple macroeconomic headwinds, including a weaker respiratory season with U.S. influenza-like illness visits down approximately 30% year-over-year, slower distributor sales in China potentially linked to proposed reimbursement rate cuts, and delayed orders in Europe, the Middle East, and Africa due to geopolitical conflict.

Despite the Q1 miss, QuidelOrtho stated that the low end of its full-year 2026 guidance remains achievable. The negative market reaction was further compounded by JP Morgan cutting its price target on the stock to $15 from $25.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1179659689"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179659689\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179659689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179659689","market":"us","top_or_hot":-1,"title":"Stock Track | Quidel Plunges 17.67% in Post-Market on Q1 Revenue Miss and Macro Pressures","media":"Stock Track","content":"<p>Quidel's stock plummeted 17.67% in post-market trading, following the company's announcement of preliminary first-quarter revenue that fell significantly short of analyst expectations.</p><p>The in vitro diagnostics company expects preliminary unaudited Q1 2026 revenue of $615 million to $620 million, well below the $677.8 million analysts had anticipated. The shortfall is attributed to multiple macroeconomic headwinds, including a weaker respiratory season with U.S. influenza-like illness visits down approximately 30% year-over-year, slower distributor sales in China potentially linked to proposed reimbursement rate cuts, and delayed orders in Europe, the Middle East, and Africa due to geopolitical conflict.</p><p>Despite the Q1 miss, QuidelOrtho stated that the low end of its full-year 2026 guidance remains achievable. The negative market reaction was further compounded by JP Morgan cutting its price target on the stock to $15 from $25.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Quidel Plunges 17.67% in Post-Market on Q1 Revenue Miss and Macro Pressures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Quidel Plunges 17.67% in Post-Market on Q1 Revenue Miss and Macro Pressures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-16 15:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Quidel's stock plummeted 17.67% in post-market trading, following the company's announcement of preliminary first-quarter revenue that fell significantly short of analyst expectations.</p><p>The in vitro diagnostics company expects preliminary unaudited Q1 2026 revenue of $615 million to $620 million, well below the $677.8 million analysts had anticipated. The shortfall is attributed to multiple macroeconomic headwinds, including a weaker respiratory season with U.S. influenza-like illness visits down approximately 30% year-over-year, slower distributor sales in China potentially linked to proposed reimbursement rate cuts, and delayed orders in Europe, the Middle East, and Africa due to geopolitical conflict.</p><p>Despite the Q1 miss, QuidelOrtho stated that the low end of its full-year 2026 guidance remains achievable. The negative market reaction was further compounded by JP Morgan cutting its price target on the stock to $15 from $25.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QDEL","symbol_name":"窥得儿医药","start_time":0,"source_url":"","article_id":"1179659689","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179659689","pubTimestamp":1776325009,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Quidel's stock plummeted 17.67% in post-market trading, following the company's announcement of preliminary first-quarter revenue that fell significantly short of analyst expectations.The in vitro...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QDEL":"窥得儿医药"},"translate_title":"个股追踪|Q1营收未达预期及宏观压力Quidel盘后暴跌17.67%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QDEL":1},"content_text":"Quidel's stock plummeted 17.67% in post-market trading, following the company's announcement of preliminary first-quarter revenue that fell significantly short of analyst expectations.The in vitro diagnostics company expects preliminary unaudited Q1 2026 revenue of $615 million to $620 million, well below the $677.8 million analysts had anticipated. The shortfall is attributed to multiple macroeconomic headwinds, including a weaker respiratory season with U.S. influenza-like illness visits down approximately 30% year-over-year, slower distributor sales in China potentially linked to proposed reimbursement rate cuts, and delayed orders in Europe, the Middle East, and Africa due to geopolitical conflict.Despite the Q1 miss, QuidelOrtho stated that the low end of its full-year 2026 guidance remains achievable. The negative market reaction was further compounded by JP Morgan cutting its price target on the stock to $15 from $25.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}